Structure-activity relationships of peptides incorporating a bioactive reverse-turn heterocycle at the melanocortin receptors: identification of a 5800-fold mouse melanocortin-3 receptor (mMC3R) selective antagonist/partial agonist versus the mouse melanocortin-4 receptor (mMC4R).

The melanocortin-3 (MC3) and melanocortin-4 (MC4) receptors regulate energy homeostasis, food intake, and associated physiological conditions. The melanocortin-4 receptor (MC4R) has been studied extensively. Less is known about specific physiological roles of the melanocortin-3 receptor (MC3R). A major obstacle to this lack of knowledge is attributed to a limited number of identified MC3R selective ligands. We previously reported a spatial scanning approach of a 10-membered thioether-heterocycle ring incorporated into a chimeric peptide template that identified a lead nM MC4R ligand. Upon the basis of those results, 17 compounds were designed and synthesized that focused upon modification in the pharmacophore domain. Notable results include the identification of a 0.13 nM potent 5800-fold mMC3R selective antagonist/slight partial agonist versus a 760 nM mMC4R full agonist (ligand 11). Biophysical experiments (two-dimensional (1)H NMR and computer-assisted molecular modeling) of this ligand resulted in the identification of an inverse γ-turn secondary structure in the ligand pharmacophore domain.

[1]  W. Garvey,et al.  Molecular characterization of human melanocortin-3 receptor ligand-receptor interaction. , 2006, Biochemistry.

[2]  N. Richards,et al.  Novel agouti-related-protein-based melanocortin-1 receptor antagonist. , 2001, Journal of medicinal chemistry.

[3]  M. Bednarek,et al.  Selective, high affinity peptide antagonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. , 2001, Journal of medicinal chemistry.

[4]  Paolo Grieco,et al.  Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. , 2002, Journal of medicinal chemistry.

[5]  R. Mains,et al.  Structure and biosynthesis of pro-adrenocorticotropin/endorphin and related peptides. , 1980, Endocrine reviews.

[6]  J. Funder,et al.  Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. , 1988, Endocrine reviews.

[7]  L. Chen,et al.  Structure-activity relationship of linear peptide Bu-His-DPhe-Arg-Trp-Gly-NH(2) at the human melanocortin-1 and -4 receptors: arginine substitution. , 2002, Bioorganic & medicinal chemistry letters.

[8]  Y. Wan,et al.  Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants. , 2001, Biochemistry.

[9]  V J Hruby,et al.  alpha-Melanotropin: the minimal active sequence in the frog skin bioassay. , 1987, Journal of medicinal chemistry.

[10]  P. Grieco,et al.  Design and synthesis of highly potent and selective melanotropin analogues of SHU9119 modified at position 6. , 2002, Biochemical and biophysical research communications.

[11]  R. Cone,et al.  A colorimetric assay for measuring activation of Gs- and Gq-coupled signaling pathways. , 1995, Analytical biochemistry.

[12]  A. Lerner,et al.  Effect of Alpha- and Beta-Melanocyte Stimulating Hormones on the Skin Colour of Man , 1961, Nature.

[13]  A. Edison,et al.  Incorporation of a bioactive reverse-turn heterocycle into a peptide template using solid-phase synthesis to probe melanocortin receptor selectivity and ligand conformations by 2D 1H NMR. , 2011, Journal of medicinal chemistry.

[14]  W. Millard,et al.  Implication of the melanocortin-3 receptor in the regulation of food intake. , 2011, European journal of pharmacology.

[15]  B. Schölkens,et al.  ACTH and alpha-MSH: cardiovascular and antiarrhythmic properties. , 1974, Archives internationales de pharmacodynamie et de therapie.

[16]  C. Haskell-Luevano,et al.  Structure–activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 at the mouse melanocortin receptors Part 3: modifications at the Arg position , 2003, Peptides.

[17]  Ximena Opitz-Araya,et al.  Exocrine Gland Dysfunction in MC5-R-Deficient Mice: Evidence for Coordinated Regulation of Exocrine Gland Function by Melanocortin Peptides , 1997, Cell.

[18]  Jinfa Ying,et al.  Solution structures of cyclic melanocortin agonists and antagonists by NMR. , 2003, Biopolymers.

[19]  M. Bednarek,et al.  Structure-function studies on the cyclic peptide MT-II, lactam derivative of α-melanotropin☆ ☆ Throughout this report, the numbering of the amino acid residues in α-MSH has been retained for all linear and cyclic peptides. , 1999, Peptides.

[20]  M. Meldal,et al.  A solid-phase approach to mouse melanocortin receptor agonists derived from a novel thioether cyclized peptidomimetic scaffold. , 2002, Journal of the American Chemical Society.

[21]  Xin-jie Chu,et al.  Structure–activity relationship of cyclic peptide penta-c[Asp-His6-DPhe7-Arg8-Trp9-Lys]-NH2 at the human melanocortin-1 and -4 receptors: His6 substitution , 2003 .

[22]  M. Tota,et al.  Molecular determinants of ligand binding to the human melanocortin-4 receptor. , 2000, Biochemistry.

[23]  Xin-jie Chu,et al.  Structure-activity relationship of linear peptide Bu-His6-DPhe7-Arg8-Trp9-Gly10-NH2 at the human melanocortin-1 and -4 receptors: DPhe7 and Trp9 substitution. , 2003, Bioorganic & medicinal chemistry letters.

[24]  C. Haskell-Luevano,et al.  Melanocortin Ligands: 30 Years of Structure—Activity Relationship (SAR) Studies , 2004 .

[25]  N. Rowland,et al.  Effect of MTII on food intake and brain c-Fos in melanocortin-3, melanocortin-4, and double MC3 and MC4 receptor knockout mice , 2010, Peptides.

[26]  J. Baik,et al.  Type I beta-turn conformation is important for biological activity of the melanocyte-stimulating hormone analogues. , 1999, European journal of biochemistry.

[27]  R. Cone,et al.  Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat , 2001, Nature Neuroscience.

[28]  V. Hruby,et al.  [half-Cys4,half-Cys10]-alpha-Melanocyte-stimulating hormone: a cyclic alpha-melanotropin exhibiting superagonist biological activity. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Kucharzik,et al.  Role of the Melanocortin System in Inflammation , 2006, Annals of the New York Academy of Sciences.

[30]  G. Rose,et al.  Turns in peptides and proteins. , 1985, Advances in protein chemistry.

[31]  Zhimin Xiang,et al.  Structure-activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH(2) at the mouse melanocortin receptors. 1. Modifications at the His position. , 2002, Journal of medicinal chemistry.

[32]  P. Grieco,et al.  Extensive structure-activity studies of lactam derivatives of MT-II and SHU-9119: their activity and selectivity at human melanocortin receptors 3, 4, and 5. , 2003, The journal of peptide research : official journal of the American Peptide Society.

[33]  M. Bednarek,et al.  1H‐NMR studies on a potent and selective antagonist at human melanocortin receptor 4 (hMC‐4R) , 2003, Biopolymers.

[34]  Richard P. Woychik,et al.  Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor , 1994, Nature.

[35]  V. Hruby,et al.  Design of potent linear α-melanotropin 4-10 analogues modified in positions 5 and 10 , 1989 .

[36]  V. Hruby,et al.  Melanotropins structural conformational and biological considerations in the development of superpotent and superprolonged analogs , 1984 .

[37]  Potent and selective peptide agonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. , 2001, Biochemical and biophysical research communications.

[38]  R. Petrovska,et al.  Melanocortin receptors form constitutive homo- and heterodimers. , 2005, Biochemical and biophysical research communications.

[39]  E. Kaiser,et al.  Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. , 1970, Analytical biochemistry.

[40]  M. Mortrud,et al.  The cloning of a family of genes that encode the melanocortin receptors. , 1992, Science.

[41]  C. Pouton,et al.  Synthesis and biological evaluation of α-MSH analogues substituted with alanine , 1994, Peptides.

[42]  David C Fry,et al.  A predictive pharmacophore model of human melanocortin-4 receptor as derived from the solution structures of cyclic peptides. , 2004, Bioorganic & medicinal chemistry.

[43]  Andrzej Wilczynski,et al.  Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands. , 2004, Journal of medicinal chemistry.

[44]  B D Sykes,et al.  Chemical shifts as a tool for structure determination. , 1994, Methods in enzymology.

[45]  Xin-jie Chu,et al.  Structure-activity relationship of linear peptide Bu-His-DPhe-Arg-Trp-Gly-NH(2) at the human melanocortin-1 and -4 receptors: histidine substitution. , 2002, Bioorganic & medicinal chemistry letters.

[46]  C. Humblet,et al.  Three-dimensional molecular models of the hMC1R melanocortin receptor: complexes with melanotropin peptide agonists. , 1996, Drug design and discovery.

[47]  M. Tschöp,et al.  MC4R Dimerization in the Paraventricular Nucleus and GHSR/MC3R Heterodimerization in the Arcuate Nucleus: Is There Relevance for Body Weight Regulation? , 2012, Neuroendocrinology.

[48]  L. Hakim Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind placebo controlled crossover study , 1999, International Journal of Impotence Research.

[49]  M. Bednarek,et al.  Analogs of MTII, lactam derivatives of alpha-melanotropin, modified at the N-terminus, and their selectivity at human melanocortin receptors 3, 4, and 5. , 1999, Biochemical and biophysical research communications.

[50]  R. Fillingim,et al.  Melanocortin-1 receptor gene variants affect pain and μ-opioid analgesia in mice and humans , 2005, Journal of Medical Genetics.

[51]  Zhimin Xiang,et al.  Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. , 2008, Journal of medicinal chemistry.

[52]  L. Stewart,et al.  The Melanocortin 3 Receptor: A Novel Mediator of Exercise-Induced Inflammation Reduction in Postmenopausal Women? , 2011, Journal of aging research.

[53]  V. Hruby,et al.  Design of Peptides, Proteins, and Peptidomimetics in Chi Space , 1997 .

[54]  M. Bogyo,et al.  Novel Aza Peptide Inhibitors and Active‐Site Probes of Papain‐Family Cysteine Proteases , 2006, Chembiochem : a European journal of chemical biology.

[55]  S. Watson,et al.  Molecular cloning of a novel melanocortin receptor. , 1993, The Journal of biological chemistry.

[56]  C. Haskell-Luevano,et al.  Design and pharmacology of peptoids and peptide-peptoid hybrids based on the melanocortin agonists core tetrapeptide sequence. , 2003, Bioorganic & medicinal chemistry letters.

[57]  V. Hruby,et al.  Design of a New Class of Superpotent Cyclic α-Melanotropins Based on Quenched Dynamic Simulations. , 1989 .

[58]  R. Cone,et al.  Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. , 1995, Journal of medicinal chemistry.

[59]  V. Hruby,et al.  4-Norleucine , 7D-phenylalanine-a-melanocyte-stimulating hormone : A highly potent a-melanotropin with ultralong biological activity ( amino acid racemization / peptide degradation / adenylate cyclase / tyrosinase / melanoma ) , 2022 .

[60]  I. Pogozheva,et al.  Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-3 receptor agonist versus antagonist activity. , 2008, Journal of medicinal chemistry.

[61]  M. Mortrud,et al.  Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. , 1994, Molecular endocrinology.

[62]  V. Hruby,et al.  Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies. , 2010, Journal of the American Chemical Society.

[63]  G. Gessa,et al.  Induction of Sexual Excitement by the Action of Adrenocorticotrophic Hormone in Brain , 1969, Nature.

[64]  V. Hruby,et al.  Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. , 1989, Journal of medicinal chemistry.

[65]  H. Schild pA, A NEW SCALE FOR THE MEASUREMENT OF DRUG ANTAGONISM , 1997, British journal of pharmacology and chemotherapy.

[66]  V. Hruby,et al.  4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Yue Feng,et al.  Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass , 2000, Nature Genetics.

[68]  V. Hruby,et al.  beta-Methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity. , 1997, Journal of medicinal chemistry.

[69]  G. Barsh,et al.  Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. , 1997, Science.

[70]  C. Haskell-Luevano,et al.  Synthesis and activity of the melanocortin Xaa-d-Phe-Arg-Trp-NH tetrapeptides with amide bond modifications. , 2004, The journal of peptide research : official journal of the American Peptide Society.

[71]  J. Hoyer,et al.  Modulation of blood pressure by central melanocortinergic pathways. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[72]  Hongmao Sun,et al.  Highly Selective Cyclic Peptides for Human Melanocortin-4 Receptor (MC-4 R): Design, Synthesis, Bioactive Conformation, and Pharmacological Evaluation as an Anti-Obesity Agent , 2001 .

[73]  C. Haskell-Luevano,et al.  Structure-activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH(2) at the mouse melanocortin receptors. 1. Modifications at the His position. , 2002, Journal of medicinal chemistry.

[74]  H. Schiöth,et al.  Further pharmacological characterization of the selective melanocortin 4 receptor antagonist HS014: comparison with SHU9119 , 1999, Neuropeptides.

[75]  J. Wikberg,et al.  Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): evaluation in vitro and in vivo. , 1998, Endocrinology.

[76]  Jinfa Ying,et al.  Design, synthesis, and biological evaluation of new cyclic melanotropin peptide analogues selective for the human melanocortin-4 receptor. , 2006, Journal of medicinal chemistry.

[77]  Xin-jie Chu,et al.  Structure-activity relationship of cyclic peptide penta-c[Asp-His(6)-DPhe(7)-Arg(8)-Trp(9)-Lys]-NH(2) at the human melanocortin-1 and -4 receptors: His(6) substitution. , 2003, Bioorganic & medicinal chemistry letters.

[78]  Michael G Kelly,et al.  Design of a new peptidomimetic agonist for the melanocortin receptors based on the solution structure of the peptide ligand, Ac-Nle-cyclo[Asp-Pro-DPhe-Arg-Trp-Lys]-NH(2). , 2003, Bioorganic & medicinal chemistry letters.

[79]  V. Hruby,et al.  NMR and quenched molecular dynamics studies of superpotent linear and cyclic α-melanotropins , 2009 .

[80]  M. Mortrud,et al.  Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[81]  W. Elliott Modulation of Blood Pressure by Central Melanocortinergic Pathways , 2010 .

[82]  A. Catania The melanocortin system in leukocyte biology , 2007, Journal of leukocyte biology.

[83]  J. Wikberg,et al.  Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA , 1992, FEBS letters.

[84]  J. Wikberg,et al.  Molecular cloning of a novel human melanocortin receptor. , 1993, Biochemical and biophysical research communications.

[85]  W. Millard,et al.  Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4 receptor polymorphisms. , 2007, Biochemistry.

[86]  Victor J. Hruby,et al.  Role of melanocortinergic neurons in feeding and the agouti obesity syndrome , 1997, Nature.

[87]  S. Watson,et al.  Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. , 1993, The Journal of biological chemistry.

[88]  G. Han,et al.  9-Fluorenylmethoxycarbonyl amino-protecting group , 1972 .

[89]  C. Haskell-Luevano,et al.  Structure-activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH(2) at the mouse melanocortin receptors: part 2 modifications at the Phe position. , 2002, Journal of medicinal chemistry.

[90]  G. Han,et al.  9-Fluorenylmethoxycarbonyl function, a new base-sensitive amino-protecting group , 1970 .

[91]  R. Woychik,et al.  Molecular characterization of the mouse agouti locus , 1992, Cell.

[92]  C. Haskell-Luevano,et al.  Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor , 2001, Regulatory Peptides.

[93]  T. Schöneberg,et al.  Mutually opposite signal modulation by hypothalamic heterodimerization of ghrelin- and melanocortin-3 receptors , 2012 .

[94]  B. Pettitt,et al.  Modeling of alpha-MSH conformations with implicit solvent. , 1999, The journal of peptide research : official journal of the American Peptide Society.

[95]  Y. Konda,et al.  Molecular cloning, expression, and characterization of a fifth melanocortin receptor. , 1994, Biochemical and biophysical research communications.

[96]  Andrzej Wilczynski,et al.  Structure-activity relationships of the unique and potent agouti-related protein (AGRP)-melanocortin chimeric Tyr-c[beta-Asp-His-DPhe-Arg-Trp-Asn-Ala-Phe-Dpr]-Tyr-NH2 peptide template. , 2005, Journal of medicinal chemistry.

[97]  V. Hruby,et al.  Topographical modification of melanotropin peptide analogues with beta-methyltryptophan isomers at position 9 leads to differential potencies and prolonged biological activities. , 1995, Journal of Medicinal Chemistry.